Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson’s Disease TORONTO, ONTARIO–(Marketwired – June 25, […]
Featured Posts
Two brothers – one an entrepreneur, the other a Columbia University psychiatrist – are claiming today that a new combination of experimental medicines may prevent suicidal thoughts in people with […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive […]
The newest HPV vaccine safely and effectively prevents at least four different kinds of cancer in the population recommended to receive it, according to a study in Pediatrics today. Gardasil […]
Effort With CDC to Collect, Analyze and Disseminate Much-Needed Sickle Cell Information ATLANTA, GA–(Marketwired – June 19, 2015) – Sickle cell disease (SCD), estimated to affect nearly 100,000 Americans, is […]
R&D efforts on the part of major biopharmaceutical companies for novel drugs to treat depression and other CNS diseases have eroded over the past decade. In fact, a study published […]
GlaxoSmithKline wants to better understand biology so it can discover more medicines, like every other drugmaker. It also wants to quit wasting money on drug candidates that look promising in […]
Easton, Maryland – June 16, 2015 – For some especially progressive pharmaceutical companies clinical research is now being used not only for developing products but for selling them, according to […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca (NYSE: AZN) today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating […]
VIENNA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced […]